Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Roongroj Bhidayasiri, Onanong Phokaewvarangkul, Karn Sakdisornchai, Kamolwan Boonpang, K. Ray Chaudhuri, Jan Parsons, Praween Lolekha, Parnsiri Chairangsaris, Prachaya Srivanitchapoom, Sharon Benedierks, Pattamon Panyakaew, Thanatat Boonmongkol, Yuwadee Thongchuam, Nitinan Kantachadvanich, Saisamorn Phumphid, Andrew H. Evans, Akravudh Viriyavejakul, Apichart Pisarnpong, Teus van Laar & Priya Jagota. (2020) Establishing apomorphine treatment in Thailand: understanding the challenges and opportunities of Parkinson’s disease management in developing countries. Expert Review of Neurotherapeutics 20:6, pages 523-537.
Read now
Read now
Mitesh Lotia & Joseph Jankovic. (2016) New and emerging medical therapies in Parkinson’s disease. Expert Opinion on Pharmacotherapy 17:7, pages 895-909.
Read now
Read now
Roberto Ceravolo, Carlo Rossi, Eleonora Del Prete & Ubaldo Bonuccelli. (2016) A review of adverse events linked to dopamine agonists in the treatment of Parkinson’s disease. Expert Opinion on Drug Safety 15:2, pages 181-198.
Read now
Read now
Articles from other publishers (16)
Fabrizio Stocchi, Olivier Rascol, Werner Poewe, K. Ray Chaudhuri, Jan Kassubek, Lydia Lopez Manzanares, Yi Zhang, Alyssa Bowling, Eric Pappert & Stacy Wu. (2023) Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson’s Disease: An Open-Label, Randomized, Crossover Study. Journal of Parkinson's Disease, pages 1-14.
Crossref
Crossref
Liqian Zhou, Yuzhuang Wang, Lihong Peng, Zejun Li & Xueming Luo. (2023) Identifying potential drug-target interactions based on ensemble deep learning. Frontiers in Aging Neuroscience 15.
Crossref
Crossref
Fabrizio Stocchi, Elizabeth L. Peckham, Maria Francesca De Pandis, Ken Sciarappa, Robert Kleiman, Felix Agbo, C. Warren Olanow, David Blum & Bradford Navia. (2022) A Randomized Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson's Disease. Clinical Pharmacology in Drug Development 11:9, pages 1068-1077.
Crossref
Crossref
Andrew Thach, Miriam L Zichlin, Noam Kirson, Karen Yang, Katherine Gaburo, Eric Pappert, Darshan Mehta & G Rhys Williams. (2022) Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease ‘OFF’ episodes. Journal of Comparative Effectiveness Research 11:4, pages 285-295.
Crossref
Crossref
Regina Katzenschlager, Werner Poewe, Olivier Rascol, Claudia Trenkwalder, Günther Deuschl, K Ray Chaudhuri, Tove Henriksen, Teus van Laar, Donna Lockhart, Harry Staines & Andrew Lees. (2021) Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. Parkinsonism & Related Disorders 83, pages 79-85.
Crossref
Crossref
Ankita Paul & Khushwant S. Yadav. (2020) Parkinson's disease: Current drug therapy and unraveling the prospects of nanoparticles. Journal of Drug Delivery Science and Technology 58, pages 101790.
Crossref
Crossref
Masaaki Kawano, Kikue Saika, Rie Takagi, Masanori Matsui & Sho Matsushita. (2020) Tannic acid acts as an agonist of the dopamine D2L receptor, regulates immune responses, and ameliorates experimentally induced colitis in mice. Brain, Behavior, & Immunity - Health 5, pages 100071.
Crossref
Crossref
Anupam Karki, Reecan Juarez, Hari K. Namballa, Ian Alberts & Wayne W. Harding. (2020) Identification of C10 nitrogen-containing aporphines with dopamine D1 versus D5 receptor selectivity. Bioorganic & Medicinal Chemistry Letters 30:8, pages 127053.
Crossref
Crossref
C Warren Olanow, Stewart A Factor, Alberto J Espay, Robert A Hauser, Holly A Shill, Stuart Isaacson, Rajesh Pahwa, Mika Leinonen, Parul Bhargava, Ken Sciarappa, Bradford Navia, David Blum & xx xx. (2020) Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. The Lancet Neurology 19:2, pages 135-144.
Crossref
Crossref
Manon Auffret, Sophie Drapier & Marc Vérin. 2020. Diagnosis and Management in Parkinson's Disease. Diagnosis and Management in Parkinson's Disease
461
475
.
Roongroj Bhidayasiri, Onanong Phokaewvarangkul, Kamolwan Boonpang, Thanatat Boonmongkol, Yuwadee Thongchuem, Nitinan Kantachadvanich & Pedro J. García Ruiz. (2019) Long-term Apomorphine Infusion Users Versus Short-term Users: An International Dual-center Analysis of the Reasons for Discontinuing Therapy. Clinical Neuropharmacology 42:5, pages 172-178.
Crossref
Crossref
Masaaki Kawano, Rie Takagi, Kikue Saika, Masanori Matsui & Sho Matsushita. (2018) Dopamine regulates cytokine secretion during innate and adaptive immune responses. International Immunology 30:12, pages 591-606.
Crossref
Crossref
Ángel Sesar, Gustavo Fernández-Pajarín, Begoña Ares, María Teresa Rivas & Alfonso Castro. (2017) Continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease: 10-year experience with 230 patients. Journal of Neurology 264:5, pages 946-954.
Crossref
Crossref
Roongroj Bhidayasiri, Pedro J. Garcia Ruiz & Tove Henriksen. (2016) Practical management of adverse events related to apomorphine therapy. Parkinsonism & Related Disorders 33, pages S42-S48.
Crossref
Crossref
Olivier Rascol. (2016) Pharmacological Insights into Levodopa-induced Motor Fluctuations in Patients with Parkinson's Disease. Movement Disorders Clinical Practice 3:6, pages 523-526.
Crossref
Crossref
Louise Lincoln, Ria Fisher, Michael J. Jackson, Peter Jenner, John Neumeyer, Anna W. Sromek, Andrew J. Lees & Sarah Rose. (2016)
Oral r-(-)-11-o-valeryl-n-
n
-propylnoraporphine reverses motor deficits in mptp-treated marmosets
. Movement Disorders 31:9, pages 1381-1388.
Crossref
Crossref